PHPBiotech.wikiThe PHP Biotech Reference

GEN01-AD platform

From PHPBiotech.wiki, a sourced reference on PHP Biotech, a preclinical oncology company

By the PHP Biotech Wiki editorial team · Published · Last updated

Short answer: GEN01-AD (“Genetically Engineered Nanobody – Active Drug”) is PHP Biotech’s name for its nanobody platform, which the company says places therapeutic peptides at defined sites inside a humanized camelid nanobody without chemical linkers.[1] A U.S. patent application on the platform was published in February 2026 and is pending.[2]

Disclosure: PHPBiotech.wiki is a reference compiled from public sources. It is not the official website of PHP Biotech International Inc.; it is produced by a marketing agency that works for PHP Biotech. It is not written or reviewed by the U.S. Food and Drug Administration or any other regulator, by the journal that published the company’s research, or by any patent office. Nothing on this site is medical advice. PHP53-nb is an investigational, preclinical product: it is not approved for any use and is not available to patients. Facts are cited to public registries, PubMed, patent records, archived web pages, press releases and the company’s own website. See the editorial policy.

What is GEN01-AD?

The company says GEN01-AD differs from conventional nanobodies, which are designed only to bind a target, because it contains defined insertion sites for therapeutic peptides that allow stable integration without linkers.[1] PHP53-nb is the lead candidate the company has built on the platform.[1][3]

Is the platform patented?

The company’s platform page calls the insertion sites “patented”.[1] The published U.S. application US 2026/0041783 A1, “Nanobody platform, Peptide-modified Nanobody, Production Process, and Use”, filed on 30 May 2025 and published on 12 February 2026, describes peptides placed in the nanobody’s CDR1 and CDR3 regions; Google Patents lists it as pending, not granted.[2] See Patents and publications.

How does the company say it is produced?

According to the company, PHP53-nb is expressed in Chinese hamster ovary (CHO) cells, plasmid optimization raised yields from 5 mg/L at lab scale to 693 mg/L, and yields above 1 g/L are needed for commercial viability.[1] These figures are the company’s own and have not been published elsewhere.

Why does the company use nanobodies?

The company argues that nanobodies, at about a tenth of the size of a conventional antibody, may penetrate tumors more deeply and provoke less immune response.[1][4] These are the company’s stated rationale, not findings in people.

How long has the platform been in development?

The company’s timeline describes five years of peptide screening that led to 3-NAntC, followed by two years designing and scaling the nanobody platform, without giving calendar years.[3]

Frequently asked questions

What does GEN01-AD stand for?

“Genetically Engineered Nanobody – Active Drug”, according to PHP Biotech.

Is GEN01-AD patented?

The company calls its insertion sites patented. The published platform application, US 2026/0041783 A1, was listed as pending on Google Patents as of 4 October 2026.

Can the platform carry other peptides?

The company says it is designed as a flexible platform for other peptide therapeutics. No other candidate has been publicly described in detail.

See also

References

  1. ^ a b c d e f “Platform”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  2. ^ a b US 2026/0041783 A1, “Nanobody platform, Peptide-modified Nanobody, Production Process, and Use” (application 19/223,678). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  3. ^ a b “About Us”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  4. ^ “Nanobodies vs. Monoclonal Antibodies” (blog post, 10 September 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.